Cancer and cancer-therapy related cognitive dysfunction: An international perspective from the Venice cognitive workshop Journal Article


Authors: Vardy, J.; Wefel, J. S.; Ahles, T.; Tannock, I. F.; Schagen, S. B.
Article Title: Cancer and cancer-therapy related cognitive dysfunction: An international perspective from the Venice cognitive workshop
Abstract: A subset of survivors has cognitive impairment after cancer treatment. This is generally subtle, but may be sustained. In October 2006, the second international cognitive workshop was held in Venice. The workshop included neuropsychologists, clinical and experimental psychologists, medical oncologists, imaging experts, and patient advocates. The main developments since the first Cognitive Workshop in 2003 have been the following. (i) studies evaluating cognitive function in patients receiving chemotherapy for cancers other than breast cancer, and in patients receiving hormonal therapy for cancer. (ii) The publication of longitudinal prospective studies which have shown that some patients already exhibit cognitive impairment on neuropsychological testing before receiving chemotherapy, and some patients have deterioration in cognitive functioning from pre- to postchemotherapy. (iii) Studies of the underlying mechanisms of cognitive impairment both in patients and in animal models. (iv) Use of structural and functional imaging techniques to study changes in brain morphology and activation patterns associated with chemotherapy. (v) At present cognitive research in cancer is limited by methodological challenges and the lack of standardization in neuropsychological studies. The current workshop addressed many of these issues and established an international task force to provide guidelines for future research and information on how best to manage these symptoms. © The Author 2007. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved.
Keywords: cancer chemotherapy; cancer survival; disease course; review; fluorouracil; nonhuman; systemic therapy; antineoplastic agents; pathophysiology; research design; chemotherapy; neurotoxicity; antineoplastic agent; neoplasms; animals; heredity; apoptosis; breast cancer; interleukin 8; risk factors; cancer therapy; risk factor; tumor necrosis factor alpha; brain; comorbidity; neuropsychological tests; interleukin 6; cognition; cooperative behavior; interdisciplinary communication; cytokine production; cognitive defect; cognition disorders; disease models, animal; psychologic test; internationality; france; neurologic examination; genetic polymorphism; interleukin 1; workshop; immune dysregulation; side-effects; interleukin 1 receptor; brain electrophysiology
Journal Title: Annals of Oncology
Volume: 19
Issue: 4
ISSN: 0923-7534
Publisher: Oxford University Press  
Date Published: 2008-04-01
Start Page: 623
End Page: 629
Language: English
DOI: 10.1093/annonc/mdm500
PUBMED: 17974553
PROVIDER: scopus
DOI/URL:
Notes: --- - "Cited By (since 1996): 68" - "Export Date: 17 November 2011" - "CODEN: ANONE" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Tim A Ahles
    182 Ahles